Abcam logo

ABC - Abcam Share Price

1398p -35.0  -2.4%

Last Trade - 27/05/20

Sector
Healthcare
Size
Large Cap
Market Cap £3.10bn
Enterprise Value £3.08bn
Revenue £273.4m
Position in Universe 197th / 1828
Bullish
Bearish
Unlock ABC Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Financial Summary
FINANCIAL BRIEF: : For the six months ended 31 December 2019, Abcam Plc revenues increased 11% to £138.2M. Net income decreased 6% to £26.1M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Selling/General/Admin. Expense increase of 37% to £56.1M (expense), R&D expenses excluding share-based payme increase of 15% to £6.8M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ABC Revenue Unlock ABC Revenue

Net Income

ABC Net Income Unlock ABC Revenue

Normalised EPS

ABC Normalised EPS Unlock ABC Revenue

PE Ratio Range

ABC PE Ratio Range Unlock ABC Revenue

Dividend Yield Range

ABC Dividend Yield Range Unlock ABC Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABC EPS Forecasts Unlock ABC Revenue
Profile Summary

Abcam plc is a global life sciences company. As a developer of reagents and tools, the Company's purpose is to serve life science researchers globally. Providing the research and clinical communities with tools and scientific support, the Company offers validated biological binders and assays to address important targets in critical biological pathways. The Company is engaged in data sharing and ecommerce in the life sciences. The Company focuses on helping advance global understanding of biology and causes of disease, which, in turn, will drive new treatments and improved health. Two-thirds of the world's 750,000 life science researchers use its affinity binders, reagents, biomarkers and assays and the Company's products are mentioned in over 20,000 of the 56,000 peer-reviewed papers published each year in the life sciences. It has approximately 10 locations located in the world, through life science research hubs, enabling local services and multi-language support.

Directors
Last Annual June 30th, 2019
Last Interim December 31st, 2019
Incorporated February 12, 1998
Public Since November 3, 2005
No. of Shareholders: n/a
No. of Employees: 1,155
Sector Healthcare
Industry Pharmaceuticals
Index FTSE Aim All Share , FTSE Aim 100 , FTSE Intl-aim UK 50 , ,
Exchange London Stock Exchange (AIM)
Shares in Issue 216,152,577
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ABC Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ABC
Upcoming Events for ABC
Frequently Asked Questions for Abcam
What is the Abcam share price?

As of 27/05/20, shares in Abcam are trading at 1398p, giving the company a market capitalisation of £3.10bn. This share price information is delayed by 15 minutes.

How has the Abcam share price performed this year?

Shares in Abcam are currently trading at 1398p and the price has moved by 0.77% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Abcam price has moved by 21.48% over the past year.

What are the analyst and broker recommendations for Abcam?

Of the analysts with advisory recommendations for Abcam, there are there are currently 0 "buy" , 6 "hold" and 1 "sell" recommendations. The overall consensus recommendation for Abcam is Sell. You can view the full broker recommendation list by unlocking its StockReport.

When will Abcam next release its financial results?

Abcam is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2020-12-31
What is the Abcam dividend yield?

The Abcam dividend yield is 0.85% based on the trailing twelve month period.

Does Abcam pay a dividend?

Last year, Abcam paid a total dividend of 0.12, and it currently has a trailing dividend yield of 0.85%. Looking ahead, Abcam has not announced an ex-dividend date yet.

When does Abcam next pay dividends?

Abcam has yet to annouce their ex-dividend date. The historic dividend yield on Abcam shares is currently 0.85%.

How do I buy Abcam shares?

To buy shares in Abcam you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Abcam?

Shares in Abcam are currently trading at 1398p, giving the company a market capitalisation of £3.10bn.

Where are Abcam shares listed? Where are Abcam shares listed?

Here are the trading details for Abcam:

Country of listing: United Kingdom
Exchange: LSE
Ticker Symbol: ABC
What kind of share is Abcam?

Based on an overall assessment of its quality, value and momentum, Abcam is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Abcam share price forecast 2020?

Shares in Abcam are currently priced at 1398p. At that level they are trading at 12.33% premium to the analyst consensus target price of 1,244.55.

Analysts covering Abcam currently have a consensus Earnings Per Share (EPS) forecast of 0.25379 for the next financial year.

How can I tell whether the Abcam share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Abcam. Over the past six months, the relative strength of its shares against the market has been 33.1%. At the current price of 1398p, shares in Abcam are trading at 14.82% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Abcam PE Ratio?

The Abcam PE ratio based on its reported earnings over the past 12 months is 40.32. The shares are currently trading at 1398p.

The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.

The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.

Who are the key directors of Abcam?

Abcam's management team is headed by:

Alan Hirzel - CEO
Giles Kerr - NID
Mara Aspinall - NID
Susan Harris - NID
Marc Perkins - GCN
Jonathan Milner - NVC
Peter Allen - NEC
Michael Baldock - CFO
Who are the major shareholders of Abcam?

Here are the top five shareholders of Abcam based on the size of their shareholding:

T. Rowe Price Associates, Inc. Investment Advisor
Percentage owned: 9.94% (21.5m shares)
Milner (Jonathan Simon) Individual Investor
Percentage owned: 8.33% (18.0m shares)
T. Rowe Price New Horizons Fund Mutual Fund
Percentage owned: 6.36% (13.7m shares)
Durable Capital Partners LP Hedge Fund
Percentage owned: 5.81% (12.6m shares)
Baillie Gifford & Co. Investment Advisor
Percentage owned: 4.84% (10.5m shares)
Similar to ABC
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.